Bionexus Gene Lab Corp. 2022 Q1 SEC Filing Summary
Business Context and Reporting Period
BioNexus Gene Lab Corp. is a Wyoming holding company with Malaysian subsidiaries operating in two principal areas: molecular and blood-based screening services through BioNexus Malaysia, and industrial chemical distribution through Chemrex. The unaudited Form 10-Q covers the three months ended March 31, 2022, with comparisons to the three months ended March 31, 2021. The company had 171,218,152 common shares outstanding as of May 12, 2022.
Key Financial Metrics
| Metric | Q1 2022 | Q1 2021 | Change |
|---|---|---|---|
| Revenue | $3.029 million | $3.449 million | Down 12.2% |
| Gross profit | $333,539 | $582,565 | Down 42.7% |
| Gross margin | 11.0% | 16.9% | Down 5.9 percentage points |
| Operating profit | $34,691 | $342,102 | Down 89.9% |
| Operating margin | 1.1% | 9.9% | Down 8.8 percentage points |
| Net profit | $17,066 | $338,744 | Down 95.0% |
| Net margin | 0.6% | 9.8% | Down 9.3 percentage points |
| Comprehensive income/(loss) | $(51,710) | $130,276 | Turned negative |
- Revenue was overwhelmingly generated by Chemrex: $3.005 million, or 99.2% of consolidated revenue. BioNexus Malaysia contributed $24,269, or 0.8%.
- Cost of revenue was $2.695 million, representing 89.0% of revenue, compared with 83.1% in the prior-year quarter.
- General and administrative expense increased 14.0% to $345,242. Finance costs were $3,326, and tax expense was $14,299.
- Foreign currency translation loss was $68,776, compared with a $208,468 loss in Q1 2021.
- Cash and cash equivalents were $1.844 million at March 31, 2022, including $1.237 million of fixed deposits and $606,850 of cash and bank balances.
- Net cash used in operating activities was $37,839, compared with $115,428 generated in Q1 2021. Net cash used in investing activities was $197,133, primarily for $172,172 of other investments and $32,191 of property and equipment.
- Working capital was $4.616 million at March 31, 2022, compared with $4.821 million at December 31, 2021.
- Total assets were $9.175 million and total liabilities were $2.047 million at March 31, 2022. Stockholders’ equity was $7.128 million.
- Finance lease obligations totaled $34,049, and operating lease liabilities totaled $37,901. The filing does not identify material traditional bank debt.
Material Changes Versus the Prior Comparable Period
- Consolidated revenue declined $420,214. Chemrex revenue fell 10.4%, primarily because the Singapore Power Project had been completed and no replacement project was reported for the quarter.
- BioNexus Malaysia revenue fell 75.1% because the Malaysian Ministry of Health outsourced COVID-19 PCR testing contract ended in December 2021. Current testing activity was primarily attributed to Singapore Airlines referrals and online marketing.
- Chemrex gross profit declined 38.5%, while BioNexus Malaysia moved from a $29,656 gross profit to a $6,563 gross loss.
- Operating expenses increased because of higher Chemrex commission payouts, fair-value investment losses, and realized foreign-exchange losses. Holding-company expenses decreased due to the absence of certain prior-year investor forum and merger-related costs.
- Net cash from operations shifted from positive to negative, while investing cash use decreased from $295,826 to $197,133.
- Other investments increased to $909,629 from $749,027 at December 31, 2021, including $172,172 of new purchases during the quarter.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- The filing provides no specific revenue, earnings, margin, or testing-volume guidance. Management stated that cash flow from operations is expected to be sufficient to sustain the current level of operations for at least the next 12 months.
- Management identified potential liquidity pressures from additional administrative and marketing personnel, website development, increased advertising, and the costs of being a public company.
- Key disclosed risks include limited operating history and business growth, uncertain efficacy of the blood-screening process, potential product-liability claims without insurance coverage, and risks of operating in Malaysia, including enforcement of judgments.
- Revenue and supplier relationships are concentrated. Two customers represented 20.78% of Q1 2022 revenue, while four suppliers represented 58.74% of purchases.
- Foreign-exchange movements remain material because Malaysian subsidiaries use the Malaysian ringgit as their functional currency while consolidated reporting is in U.S. dollars.
- Management identified a material weakness in internal control over financial reporting related to inadequate monitoring and segregation of duties. The company stated that no audit adjustments resulted, but the weakness could permit a material misstatement. Remediation includes expanding the board, separating executive and financial responsibilities, and adding personnel or outside support.
- The financial statements are unaudited, and management cautioned that quarterly results are not necessarily indicative of full-year results. No material pending legal proceedings or subsequent events were reported through May 12, 2022.
Important Facts for Investors to Verify
- Whether Chemrex can replace the completed Singapore Power Project and sustain revenue and gross-margin performance.
- Whether BioNexus Malaysia can rebuild screening revenue following the termination of the Ministry of Health PCR contract.
- Collection of the $3.035 million trade-receivables balance, for which management recorded no allowance for doubtful accounts.
- Progress and effectiveness of remediation for the material internal-control weakness.
- Liquidity impact of continued negative operating cash flow, investment purchases, customer and supplier concentration, and Malaysian ringgit/U.S. dollar fluctuations.
- The composition, valuation volatility, and strategic purpose of the $909,629 other-investments portfolio.